• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实性/囊性肾瘤、上皮性肾母细胞瘤及两者重叠性病变的分子特征:全外显子组和转录组测序分析的综合研究。

Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis.

机构信息

Departments of Pathology and Laboratory Medicine.

Department of Anatomic Pathology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi.

出版信息

Appl Immunohistochem Mol Morphol. 2022 Apr 1;30(4):257-263. doi: 10.1097/PAI.0000000000000996.

DOI:10.1097/PAI.0000000000000996
PMID:35384875
Abstract

Metanephric adenoma (MA) and Wilms tumor (WT) represent 2 prototypes of primary renal neoplasms closely resembling embryonal renal tubules. Tumors with overlapping features may occur, requiring differential diagnoses between the 2. Evidence of divergent oncogenic pathways has been reported, suggesting that MA is driven by BRAF mutation while most WT is of the BRAF wild-type. We collected 4 MA cases, 3 cases of monophasic epithelial WT, and 1 overlap metanephric tumor that contains both conventional MA and high-grade components similar to epithelial WT. Whole-exome sequencing and whole transcriptome sequencing were performed to discover mutations, somatic copy number variation, and differential expression. The findings were compared with those of WT of the TARGET database (WT-TARGET). BRAF V600E mutation was detected in all MAs as well as the overlap tumor but was undetectable in all epithelial WTs and WT-TARGET. The overlap tumor showed an additional pathogenic mutation of SETD2. Three frequent gene mutations observed in WT-TARGET were not common in epithelial WT, in which the mutations appeared sporadic. The profiles of recurrent copy number variations were all different among MA, epithelial WT, and WT-TARGET. Differential expression and unsupervised hierarchical cluster analyses revealed distinct clusters of the 3 categories. Remarkably, the overlap tumor coclustered with MA, separated from epithelial WT and WT-TARGET. The distinctiveness of MA and WT were demonstrated corresponding to BRAF-mutated and non-BRAF-mutated pathways from the molecular perspective. BRAF assay has diagnostic implication for overlap tumors.

摘要

后肾腺瘤 (MA) 和肾母细胞瘤 (WT) 代表了两种紧密类似于胚胎肾小管的原发性肾肿瘤原型。具有重叠特征的肿瘤可能会发生,需要对这两种肿瘤进行鉴别诊断。已经报道了具有不同致癌途径的证据,表明 MA 由 BRAF 突变驱动,而大多数 WT 是 BRAF 野生型。我们收集了 4 例 MA 病例、3 例单相上皮 WT 病例和 1 例重叠性后肾母细胞瘤,该肿瘤包含常规 MA 和类似于上皮 WT 的高级别成分。进行了全外显子组测序和全转录组测序以发现突变、体细胞拷贝数变异和差异表达。将这些发现与 TARGET 数据库中的 WT(WT-TARGET)进行比较。所有 MA 以及重叠性肿瘤中均检测到 BRAF V600E 突变,但所有上皮 WT 和 WT-TARGET 中均未检测到。重叠性肿瘤显示出 SETD2 的另外一个致病性突变。在 WT-TARGET 中观察到的 3 个常见基因突变在上皮 WT 中并不常见,这些突变似乎是散发性的。MA、上皮 WT 和 WT-TARGET 之间的反复出现的拷贝数变异谱均不同。差异表达和无监督层次聚类分析揭示了这 3 个类别之间的不同聚类。值得注意的是,重叠性肿瘤与 MA 共同聚类,与上皮 WT 和 WT-TARGET 分离。从分子角度证明了 MA 和 WT 的独特性对应于 BRAF 突变和非 BRAF 突变途径。BRAF 检测对重叠性肿瘤具有诊断意义。

相似文献

1
Molecular Characterization of Metanephric Adenoma, Epithelial Wilms Tumor, and Overlap Lesions: An Integrated Whole-exome and Transcriptome Sequencing Analysis.实性/囊性肾瘤、上皮性肾母细胞瘤及两者重叠性病变的分子特征:全外显子组和转录组测序分析的综合研究。
Appl Immunohistochem Mol Morphol. 2022 Apr 1;30(4):257-263. doi: 10.1097/PAI.0000000000000996.
2
Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.后肾腺瘤-上皮性肾母细胞瘤重叠病变:BRAF 状态分析。
Am J Surg Pathol. 2019 Sep;43(9):1157-1169. doi: 10.1097/PAS.0000000000001240.
3
[Molecular features of metanephric adenoma and their values in differential diagnosis].[后肾腺瘤的分子特征及其在鉴别诊断中的价值]
Zhonghua Bing Li Xue Za Zhi. 2017 Jan 8;46(1):38-42. doi: 10.3760/cma.j.issn.0529-5807.2017.01.009.
4
[Clinicopathological features of adult Wilms tumor with BRAF V600E mutation].[伴有BRAF V600E突变的成人肾母细胞瘤的临床病理特征]
Zhonghua Bing Li Xue Za Zhi. 2023 Dec 8;52(12):1210-1215. doi: 10.3760/cma.j.cn112151-20230908-00154.
5
KANK1-NTRK3 fusions define a subset of BRAF mutation negative renal metanephric adenomas.KANK1-NTRK3融合基因定义了一部分BRAF突变阴性的肾后肾腺瘤。
BMC Med Genet. 2020 Oct 12;21(1):202. doi: 10.1186/s12881-020-01143-6.
6
BRAF mutations in pediatric metanephric tumors.小儿后肾肿瘤中的BRAF突变
Hum Pathol. 2015 Aug;46(8):1153-61. doi: 10.1016/j.humpath.2015.03.019. Epub 2015 Apr 21.
7
Molecular characterisation of metanephric adenomas beyond BRAF: genetic evidence for potential malignant evolution.肾后肾腺瘤超出BRAF基因的分子特征:潜在恶性进展的遗传学证据
Histopathology. 2020 Jun;76(7):1084-1090. doi: 10.1111/his.14094. Epub 2020 May 11.
8
Atypical metanephric adenoma: Shares similar histopathological features and molecular changes of metanephric adenoma and epithelial-predominant Wilms' tumor.非典型后肾腺瘤:具有与后肾腺瘤和上皮为主型肾母细胞瘤相似的组织病理学特征及分子改变。
Front Oncol. 2022 Oct 14;12:1020456. doi: 10.3389/fonc.2022.1020456. eCollection 2022.
9
Adult Wilms Tumor: Genetic Evidence of Origin of a Subset of Cases From Metanephric Adenoma.成人肾母细胞瘤:来自后肾腺瘤的一部分病例的遗传起源证据。
Am J Surg Pathol. 2022 Jul 1;46(7):988-999. doi: 10.1097/PAS.0000000000001864. Epub 2022 Feb 21.
10
BRAF mutations in metanephric adenoma of the kidney.肾脏后肾腺瘤中的 BRAF 突变。
Eur Urol. 2012 Nov;62(5):917-22. doi: 10.1016/j.eururo.2012.05.051. Epub 2012 Jun 9.

引用本文的文献

1
Epithelial Predominant Wilms Tumor in an Adult Patient: Case Report and Literature Review.成年患者的上皮型为主的肾母细胞瘤:病例报告及文献综述
J Kidney Cancer VHL. 2024 Aug 12;11(3):33-39. doi: 10.15586/jkcvhl.v11i3.329. eCollection 2024.
2
Renal Mass Found on Imaging of Spine for Back Pain: An Incidental Finding.因背痛行脊柱影像学检查时发现肾肿物:一项偶然发现。
Cureus. 2022 Nov 8;14(11):e31267. doi: 10.7759/cureus.31267. eCollection 2022 Nov.
3
Atypical metanephric adenoma: Shares similar histopathological features and molecular changes of metanephric adenoma and epithelial-predominant Wilms' tumor.
非典型后肾腺瘤:具有与后肾腺瘤和上皮为主型肾母细胞瘤相似的组织病理学特征及分子改变。
Front Oncol. 2022 Oct 14;12:1020456. doi: 10.3389/fonc.2022.1020456. eCollection 2022.